$250.33-2.92 (-1.15%)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $250.33. Wall Street consensus targets $627.59 (17 analysts), implying a +150.7% move over the next 12 months. The stock is currently 32% below its 52-week high of $366.52, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study. This research evaluated the effectiveness of vormatrigine as a treatment for individuals with focal onset seizures. This study […]
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
Praxis Precision Medicines paused enrollment in its POWER2 study after vormatrigine did not meet the primary endpoint in the POWER1 trial for focal onset seizures. The company plans to reassess the vormatrigine program following the POWER1 outcome. For investors watching NasdaqGS:PRAX, this setback affects a key part of the epilepsy pipeline at a time when the stock has already seen sharp moves. Shares recently closed at $258.08, with the stock down 26.4% over the past week and 20.4% over...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.45%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.48%. June E-mini S&P futures (ESM26 ) rose +0.14%, and June E-mini Nasdaq futures...
Praxis Precision Medicines unexpectedly halted enrollment in a late-stage study of its seizure drug. Praxis stock tumbled.